Direct delivery

Why Deerfield led $22.6M series A for mitochondrial disease play Chondrial

Preclinical proof-of-concept data for a Friedreich’s ataxia protein replacement therapy convinced Deerfield Management to lead a series A round for Chondrial Therapeutics Inc.

Chondrial raised the first undisclosed tranche of the $22.6 million round on Jan. 31. Wake Forest

Read the full 391 word article

How to gain access

Continue reading with a
two-week free trial.